Literature DB >> 16096377

Analysis of BRAF mutation in primary and metastatic melanoma.

Massimo Libra1, Grazia Malaponte, Patrick M Navolanic, Pietro Gangemi, Valentina Bevelacqua, Lidia Proietti, Bibiana Bruni, Franca Stivala, Maria C Mazzarino, Salvatore Travali, James A McCubrey.   

Abstract

Mutation of BRAF has been proposed to contribute to melanoma development. However, it remains unclear whether or not BRAF mutation is associated with any particular stage of melanoma progression. Tumor biopsy specimens from patients with melanoma were analyzed to determine whether the frequency of BRAF mutation in metastatic melanoma differed from primary melanoma. BRAF mutation was present in 15 of 23 (61%) patients with primary melanoma and in 7 of 12 (58%) patients with metastatic melanoma. These results suggest that BRAF mutation in melanoma is most likely to occur prior to the development of metastatic disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16096377     DOI: 10.4161/cc.4.10.2026

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  27 in total

Review 1.  Melanoma: from mutations to medicine.

Authors:  Hensin Tsao; Lynda Chin; Levi A Garraway; David E Fisher
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

Review 2.  Growth factors and oncogenes as targets in melanoma: lost in translation?

Authors:  Lawrence Kwong; Lynda Chin; Stephan N Wagner
Journal:  Adv Dermatol       Date:  2007

3.  P21-activated kinase 1 regulates resistance to BRAF inhibition in human cancer cells.

Authors:  Mahamat Babagana; Sydney Johnson; Hannah Slabodkin; Wiam Bshara; Carl Morrison; Eugene S Kandel
Journal:  Mol Carcinog       Date:  2017-02-23       Impact factor: 4.784

4.  Identification of aurora kinase B and Wee1-like protein kinase as downstream targets of (V600E)B-RAF in melanoma.

Authors:  Arati Sharma; SubbaRao V Madhunapantula; Raghavendra Gowda; Arthur Berg; Rogerio I Neves; Gavin P Robertson
Journal:  Am J Pathol       Date:  2013-02-12       Impact factor: 4.307

5.  Implication of RAF and RKIP genes in urinary bladder cancer.

Authors:  Apostolos Zaravinos; Maria Chatziioannou; George I Lambrou; Ioannis Boulalas; Dimitris Delakas; Demetrios A Spandidos
Journal:  Pathol Oncol Res       Date:  2010-09-18       Impact factor: 3.201

6.  Lack of JAK2 activating non-synonymous mutations in diffuse large B-cell tumors: JAK2 deregulation still unexplained.

Authors:  Thomas E Witzig; Tammy L Price-Troska; Mary J Stenson; Mamta Gupta
Journal:  Leuk Lymphoma       Date:  2012-08-17

7.  Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression.

Authors:  Igor Puzanov; Ravi K Amaravadi; Grant A McArthur; Keith T Flaherty; Paul B Chapman; Jeffrey A Sosman; Antoni Ribas; Mark Shackleton; Patrick Hwu; Bartosz Chmielowski; Keith B Nolop; Paul S Lin; Kevin B Kim
Journal:  Eur J Cancer       Date:  2015-05-13       Impact factor: 9.162

Review 8.  Biological challenges of BRAF inhibitor therapy.

Authors:  Igor Puzanov; Patrick Burnett; Keith T Flaherty
Journal:  Mol Oncol       Date:  2011-02-16       Impact factor: 6.603

9.  ATG5 Mediates a Positive Feedback Loop between Wnt Signaling and Autophagy in Melanoma.

Authors:  Abibatou Ndoye; Anna Budina-Kolomets; Curtis H Kugel; Marie R Webster; Amanpreet Kaur; Reeti Behera; Vito W Rebecca; Ling Li; Patricia A Brafford; Qin Liu; Y N Vashisht Gopal; Michael A Davies; Gordon B Mills; Xiaowei Xu; Hong Wu; Meenhard Herlyn; Michael C Nicastri; Jeffrey D Winkler; Maria S Soengas; Ravi K Amaravadi; Maureen E Murphy; Ashani T Weeraratna
Journal:  Cancer Res       Date:  2017-09-08       Impact factor: 12.701

10.  The response to PAK1 inhibitor IPA3 distinguishes between cancer cells with mutations in BRAF and Ras oncogenes.

Authors:  Ruchi Singhal; Eugene S Kandel
Journal:  Oncotarget       Date:  2012-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.